ArticleApplied microbiology and biotechnology2023
Development and evaluation of a blocking ELISA for serological diagnosis of equine infectious anemia.
Article in Applied microbiology and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Vector-borne diseases-knowledge maps.EFSA journal. European Food Safety Authority · 2026Article
- A Label-Free blocking immunoassay to evaluate Anti-Adalimumab antibody activity in clinical samples.Journal of mass spectrometry and advances in the clinical lab · 2025Article
- Development of a Broad-Spectrum Antigen-Capture ELISA Using Combined Anti-p26 Polyclonal and Monoclonal Antibodies for Detection of Equine Infectious Anemia Virus.Microorganisms · 2025Article
- Development of a colloidal gold immunochromatographic strip to detect equine infectious anemia virus.Virology journal · 2025Article
- Global prevalence and risk factors of equine infectious anemia: A systematic review and meta-analysis.Veterinary world · 2025Review
- Serodiagnosis of equine infectious anemia by indirect ELISA based on a novel synthetic peptide derived from gp45 glycoprotein.Veterinary research communications · 2025Article
- Development and Application of an Antigen Capture ELISA for the Detection of Enzootic Nasal Tumor Virus-2.Transboundary and emerging diseases · 2025Article
- Recombinant CA Protein-Based ELISA for Serological Detection of Small Ruminant Lentiviruses Antibodies.Transboundary and emerging diseases · 2025Article
- Development and evaluation of a test strip for the rapid detection of antibody against equine infectious anemia virus.Applied microbiology and biotechnology · 2024Article
- Fluorescence Polarization Assay for Infection Diagnostics: A Review.Molecules (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 5 countries.
Funding
Abstract
Equine infectious anemia (EIA) is an important viral disease characterized by persistent infection in equids worldwide. Most EIA cases are life-long virus carriers with low antibody reactions and without the appearance of clinical symptoms. A serological test with high sensitivity and specificity is required to detect inapparent infection. In this study, a B-cell common epitope-based blocking ELISA (bELISA) was developed using a monoclonal antibody together with the EIAV p26 protein labelled with HRP. The test has been evaluated against the standard and with field serum samples globally. This bELISA test can be completed within 75 min, and the sensitivity is higher than those of either the AGID or one commercial cELISA kit. This bELISA assay was 8-16 times more analytically sensitive than AGID, and 2 to 4 times more analytically sensitive than one cELISA kit by testing three sera from the USA, Argentina, and China, respectively. The 353 serum samples from Argentina were tested, in comparison with AGID, the diagnostic sensitivity and specificity of our bELISA assay were 100% (154/154) and 97.0% (193/199), respectively, and the accuracy of the bELISA test was 98.3%. The bELISA test developed in this study is a rapid, sensitive, specific method for the detection of EIAV infection, and could be a promising candidate for use in the monitoring of the EIA epidemic worldwide. KEY POINTS: • A universal epitope-based blocking enzyme-linked immunosorbent assay (bELISA) was developed for detection of antibodies to EIAV. • The bELISA assay can be used to test EIAV serum samples from different regions of the world including North America, South America, Europe, and Asia. • The bELISA assay was evaluated in three different international labs and showed a better performance than other commercial kits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.